Business Wire

BOEHRINGER-INGELHEIM

12.2.2020 11:19:05 CET | Business Wire | Press release

Share
CARMELINA® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes

Boehringer Ingelheim have announced the results of a subgroup analysis of the CARMELINA® trial which demonstrate that linagliptin did not increase the risk of adverse cardiovascular events or hypoglycemia compared with placebo in older people with type 2 diabetes.1 The findings have been published in the Diabetes Obesity and Metabolism journal.

Population aging has shifted the epidemiology of diabetes towards older age.1 Currently, approximately 136 million of the estimated 463 million people with diabetes are aged over 65 years.2 However, despite the high prevalence, older patients have historically been underrepresented in clinical trials of glucose-lowering drugs.3

The recent CARMELINA® cardiovascular outcome trial enrolled people aged 18 years and older with no maximum age restriction.4 The prespecified CARMELINA® subgroup analysis evaluated clinical outcomes and adverse events with the main findings grouped into the following predefined age categories: <65, 65 to <75, and ≥75 years.1

“This subset analysis shines a spotlight on the older population living with type 2 diabetes. These individuals can be frail, have a high rate of comorbidities and can be on multidrug regimens, all of which present a challenge for their glucose management,” said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “As the older population also has the highest incidence of type 2 diabetes of any age group, this analysis will be invaluable in helping clinicians manage the treatment of this patient group, previously underrepresented in clinical studies.”

Linagliptin did not increase the risk of adverse kidney outcomes, cardiovascular events or hospitalization for heart failure compared with placebo across age groups.1 The incidence of adverse events, including hypoglycemia, increased with age but was similar with linagliptin and placebo despite HbA1c reduction with linagliptin.1 Linagliptin improved glycemic control compared with placebo in all age groups.1

“Their advanced age, combined with established cardiovascular and/or kidney disease, means the older population of CARMELINA® was comprised of high-risk individuals with type 2 diabetes,” continued Dr. Jamal. “The results should reassure healthcare professionals that linagliptin is suitable for a wide patient population to improve glycemic control whilst ensuring cardiovascular and renal safety.”

About CARMELINA®

CARMELINA® is a multi-national, randomized, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.4,5 The study was designed to assess the effect of linagliptin (5mg once daily) compared to placebo (both added to standard of care) on cardiovascular outcomes in adults with type 2 diabetes and high cardiovascular risk, the majority of whom also had kidney disease.4,5 This population of people with high risk of cardiovascular and/or kidney disease reflects patients that doctors see in their daily practice.6 Standard of care included both glucose lowering agents and cardiovascular drugs (including antihypertensive and lipid lowering agents).

CARMELINA® was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. Compared to other recently reported outcome trials of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes, CARMELINA® included the highest proportion of patients with impaired kidney function.7 *

To learn more about CARMELINA® , please visit: https://www.carmelinatrial.com/

About Trajenta® (linagliptin)

Trajenta® is a one dose, once daily DPP-4 inhibitor that provides significant efficacy in the reduction of blood sugar levels for adults with type 2 diabetes. It can be prescribed for adults with type 2 diabetes regardless of age, disease duration, ethnicity, body mass index (BMI), liver and kidney function.8 Trajenta® has the lowest kidney excretion rate of all globally available DPP-4 inhibitors.9–12

Linagliptin is developed and commercialized by the Boehringer Ingelheim and Eli Lilly and Company Alliance.

About our cardiovascular outcome trials

Cardiovascular outcome trials are highly clinically relevant, as cardiovascular disease is a major complication and the leading cause of death in type 2 diabetes. Worldwide, most people with type 2 diabetes die of a cardiovascular event.13 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME® with the SGLT2 inhibitor, empagliflozin, which reduced the relative risk of cardiovascular death by 38 percent in adults with type 2 diabetes and established cardiovascular disease, on top of standard of care.†‡14–16 As a result, empagliflozin was the first oral type 2 diabetes medicine to have either a cardiovascular indication or data on the reduction of the risk of cardiovascular death included in the label in many countries.14,15

CAROLINA® is one of two cardiovascular outcome trials with the DPP-4 inhibitor, linagliptin.17,18 CAROLINA® and the CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk trial (CARMELINA® )4,5 provide one of the most comprehensive datasets on the long-term safety of a DPP-4 inhibitor.

CARMELINA® is a multi-national, randomized, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.4,5 CARMELINA® studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.4,5 The trial met its primary endpoint,§ with linagliptin demonstrating a similar cardiovascular safety profile compared to placebo when added to standard of care.5 CARMELINA® also included a key secondary composite endpoint,** showing a similar kidney safety profile compared to placebo.5 The overall safety profile of linagliptin in CARMELINA® was consistent with previous data and no new safety signals were observed.5,6 CARMELINA® also showed a similar rate of hospitalization for heart failure for linagliptin compared to placebo.5

To learn more about CAROLINA® and CARMELINA® , please visit: https://www.carmelinatrial.com/ .

Please click on the following link for ‘Notes to Editors’ and ‘References’ https://www.boehringer-ingelheim.com/press-release/CARMELINA-elderly-analysis

* Glomerular filtration rate below 60 mL/min/1.73m2
†
Adult patients with type 2 diabetes and coronary artery disease, peripheral artery disease or a history of MI or stroke
‡ Standard of care included cardiovascular medications and blood sugar lowering agents given at the discretion of physicians
§ Primary endpoint defined as time to first occurrence of the 3P-MACE (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke)
** Key secondary endpoint defined as time to first occurrence of sustained end stage kidney disease (ESKD), death due to kidney disease, or a sustained decrease in eGFR from baseline of ≥40 percent compared to placebo

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sila Inks Long-Term Offtake Deal with Panasonic Energy to Power Domestic Battery Production18.11.2026 15:00:00 CET | Press release

Agreement to deliver Sila’s Titan Silicon® Si/C anode to Panasonic’s U.S. manufacturing sites, fortifying domestic battery supply chain resilience and advanced technology capabilities. Sila, a leading battery technology and materials company, today announced a commercial offtake agreement with Panasonic Energy Corporation of North America. The multi-year agreement is part of a long-term commercial relationship with the potential for over $1 billion of offtake over time. Sila will supply its proprietary Titan Silicon® silicon-carbon (Si/C) anode material from its Moses Lake, Washington plant to power Panasonic battery cells. The partnership is also expected to support significant manufacturing and construction job creation in the United States. With Sila’s U.S.-based anode production underpinned by proprietary American technology and know-how, Panasonic and its OEM customers gain a clearer path toward a more secure, resilient, and sustainable domestic supply chain. This press release fe

Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization18.11.2026 15:00:00 CET | Press release

Rimini Cloud™ for SAP offers a smart path to modern cloud infrastructure without the risk of ERP reimplementation, forced subscription conversion or disruption to existing SAP investments Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced an expanded strategic partnership with American Digital Corporation to give SAP licensees a lower-risk, more flexible path to cloud modernization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118330258/en/ Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization Through the expanded relationship, American Digital will serve as a solution partner for Rimini Cloud™ for SAP, helping SAP ECC and S/4HANA licensees move their existing SAP systems to modern cloud infrastructure without requiring ERP reim

Two Cessna SkyCourier Aircraft Enter Aero-Medical Service With Delivery to Tassili Travail Aérien18.11.2026 15:00:00 CET | Press release

First SkyCouriers flying in Africa will support medical evacuation missions in Algeria’s energy sector Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced it has delivered two Cessna SkyCourier aircraft equipped for aero-medical missions to Tassili Travail Aérien (TTA) of Algeria. The aircraft are the first aero-medical SkyCouriers in Africa and the first customer SkyCouriers to enter service on the continent, expanding the aircraft’s global presence and demonstrating its versatility for critical special missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015092210/en/ Textron Aviation completes delivery of Africa’s first two aero-medical equipped Cessna SkyCourier aircraft to Tassili Travail Aérien, also marking the first SkyCourier deliveries in Africa, expanding the aircraft’s special-mission capabilities. The two aircraft will support TTA’s passenger transportation and aero-medical evacuati

KŌZĒ Stays Launches International Expansion with More Than 1,200 Properties18.11.2026 14:28:00 CET | Press release

The Canadian hospitality brand expands its collection across more than 33 countries and more than 500 cities, introducing exclusive member privileges through KŌZĒ Privé. KŌZĒ Stays announces a major international expansion, bringing its curated portfolio to more than 1,200 properties worldwide. Following eight consecutive years of rapid growth, the company is building on its established presence in Mont-Tremblant and the Laurentians to pursue a broader ambition in international hospitality. The expanded collection spans French and Swiss alpine chalets, Riviera villas near Monaco, Lake Como residences, private retreats in St. Barths and homes on Dubai’s Palm Jumeirah. Available through The KŌZĒ Collection, these properties extend the brand’s reach into some of the world’s most sought-after destinations. Canadian Roots, International Ambition “A guest who loves their stay with us in Mont-Tremblant should be able to book their next trip, whether that’s Verbier, St. Barths or Lake Como, kn

Blue Yonder Announces New Leadership18.11.2026 14:03:00 CET | Press release

CTO Salil Joshi Named Interim CEO to Lead Next Phase of Growth with Accelerated Innovation and Expanded Use of Company’s Technology Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye